Patent Oppositions in metabolic drugs industry

Explore the competitive field of metabolic drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in metabolic drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Jun 4, 2026
CompanyTotal Oppositions
NOVARTIS182
BOEHRINGER INGELHEIM112
NOVO NORDISK89
AMGEN44
BRISTOL MYERS SQUIBB43
NUTRICIA43
F HOFFMANN LA ROCHE37
CELGENE37
NESTLE37
PFIZER31

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the metabolic drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the metabolic drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Jun 4, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECAMay 12, 2026SANDOZ
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKMay 6, 2026KRKA
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKMay 5, 2026ZENTIVA
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKApr 28, 2026SANDOZ
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKApr 19, 2026TEVA PHARMACEUTICALS
Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHEApr 16, 2026STORZ
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKApr 13, 2026ELKINGTON AND FIFE
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression Innpm1MEMORIAL SLOAN KETTERING CANCER CENTERApr 9, 2026ARROWHOUSE
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKApr 9, 2026MAIWALD
Prebiotic For Treating Disorders Associated With Disturbed Composition Or Functionality Of The Intestinal MicrobiomeNUTRILEADSApr 9, 2026NUTRICIA

To stay ahead in the competitive metabolic drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the metabolic drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Jun 4, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS23
Apr 14, 2021Methods And Compositions For Treating CancerJANSSEN ONCOLOGY22
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM19
Aug 6, 2025Use Of Long-Acting Glp-1 PeptidesNOVO NORDISK18
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofAMGEN EUROPE15
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI13
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12
Aug 18, 2021Formulations Of EnzalutamideMEDIVATION PROSTATE THERAPEUTICS12
Dec 18, 2024Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIM11
Mar 2, 2022Modified Nucleoside, Nucleotide, And Nucleic Acid CompositionsMODERNA10